Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Retinal Pigment Epithelium

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43881   clinical trials with a EudraCT protocol, of which   7295   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    41 result(s) found for: Retinal Pigment Epithelium. Displaying page 1 of 3.
    1  2  3  Next»
    EudraCT Number: 2005-001722-92 Sponsor Protocol Number: 1 Start Date*: 2005-10-12
    Sponsor Name:The Ludwig Boltzmann Institute for Retinology and Biomicroscopic Lasersurgery
    Full Title: Systemic Bevacizumab (Avastin®) Therapy for Exudative Neovascular Age-Related Macular Degeneration (BEAT-AMD-Study)
    Medical condition: Age related macular degeneration (AMD) patients with fibrovascular pigment epithelium detachment (PED), subfoveal choroidal neovascularisations (CNV) extending under the geometric center of the fov...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2014-002384-15 Sponsor Protocol Number: 3.0 Start Date*: 2014-10-23
    Sponsor Name:Universitätsklinik für Augenheilkunde und Optometrie
    Full Title: Intravitreal Aflibercept treatment in RAP-Lesions, PED, hemorrhagic CNV and PCV
    Medical condition: Exsudative Maculopathies
    Disease: Version SOC Term Classification Code Term Level
    17.0 10015919 - Eye disorders 10063381 Polypoidal choroidal vasculopathy PT
    17.0 10015919 - Eye disorders 10052501 Detachment of retinal pigment epithelium PT
    17.0 10015919 - Eye disorders 10069125 Retinal angiomatous proliferation LLT
    17.0 10015919 - Eye disorders 10060823 Choroidal neovascularisation PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2012-000800-13 Sponsor Protocol Number: V1 Start Date*: 2013-01-24
    Sponsor Name:Universitätsklinik für Augenheilkunde und Optometrie
    Full Title: Influence of sustained-release dexamethasone on intraocular cytokines and growth factors and retinal blood vessels in retinal vein occlusion
    Medical condition: Retinal vein occlusion
    Disease: Version SOC Term Classification Code Term Level
    14.1 10015919 - Eye disorders 10066426 Hemiretinal vein occlusion LLT
    14.1 10015919 - Eye disorders 10007972 Central retinal vein occlusion LLT
    14.1 10015919 - Eye disorders 10038907 Retinal vein occlusion PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2014-001085-10 Sponsor Protocol Number: CRFB002AGB17 Start Date*: 2014-09-08
    Sponsor Name:Novartis Pharmaceuticals UK Ltd
    Full Title: A phase IV, prospective, open label, uncontrolled, European study in patients with neovascular age-related macular degeneration (nAMD), evaluating the efficacy and safety of switching from intravit...
    Medical condition: Visual impairment due to neovascular AMD
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004853 10060837 Choroidal neovascularization LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2021-001058-73 Sponsor Protocol Number: BEY-RAP.V1.0 Start Date*: 2021-06-23
    Sponsor Name:Fakultní nemocnice Královské Vinohrady
    Full Title: Brolucizumab vs. Aflibercept for Retinal Angiomatous Proliferation - Prospective Randomised Study
    Medical condition: Retinal angiomatous proliferation form of neovascular age related macular degeneration (AMD).
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2020-002349-40 Sponsor Protocol Number: CRTH258A2303E1 Start Date*: 2020-11-17
    Sponsor Name:Novartis Pharma AG
    Full Title: A 56-week phase IIIb/IV, open-label, one-arm extension study to assess the efficacy and safety of brolucizumab 6mg in a Treat-to-Control regimen with maximum treatment intervals up to 20 weeks for ...
    Medical condition: neovascular Age-related Macular Degeneration
    Disease: Version SOC Term Classification Code Term Level
    20.0 10015919 - Eye disorders 10071129 Neovascular age-related macular degeneration PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) PT (Completed) CZ (Completed) SE (Completed) BE (Completed) DE (Completed) IT (Ongoing)
    Trial results: View results
    EudraCT Number: 2007-005462-12 Sponsor Protocol Number: LUTA1 Start Date*: 2007-12-11
    Sponsor Name:St. Eriks Eye Hospital
    Full Title: A prospective, randomized, masked and controlled trial of intravitreal ranibizumab (Lucentis®) combined with transpupillary thermotherapy (TTT) in patients with neovascular age-related macular dege...
    Medical condition: Age-related macular degeneration (AMD) is the leading cause of visual impairment and social blindness in people 60 years or older. Approximately 80% of patients with severe visual loss exhibit neov...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2013-005081-19 Sponsor Protocol Number: 1 Start Date*: 2014-07-10
    Sponsor Name:HOSPICES CIVILS DELYON
    Full Title: Phase II study evaluating the efficacy of aflibercept for the treatment of idiopathic choroidal neovascularization in young subjects: the INTUITION study
    Medical condition: idiopathic choroidal neovascularization
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004853 10060837 Choroidal neovascularization LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2016-002109-20 Sponsor Protocol Number: AAV2-hRPE65v2-301 Start Date*: 2016-10-24
    Sponsor Name:Spark Therapeutics, Inc.
    Full Title: A Safety and Efficacy Study in Subjects with Leber Congenital Amaurosis (LCA) Using Adeno-Associated Viral Vector to Deliver the Gene for Human RPE65 to the Retinal Pigment Epithelium (RPE) [AAV2-h...
    Medical condition: Leber Congenital Amaurosis (LCA)
    Disease: Version SOC Term Classification Code Term Level
    19.0 10010331 - Congenital, familial and genetic disorders 10070667 Leber's congenital amaurosis PT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2018-004486-13 Sponsor Protocol Number: QL1205-002 Start Date*: 2019-04-18
    Sponsor Name:Qilu Pharmaceutical Co., Ltd.
    Full Title: A Randomized, Phase 3, Double-masked, Parallel-group, Multicenter Study to Compare Efficacy and Safety of QL1205 Versus Lucentis® in Subjects With Neovascular Age-related Macular Degeneration
    Medical condition: Subjects With Wet (neovascular) Age-related Macular Degeneration (wAMD), aged ≥50 years
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004853 10075568 Wet age-related macular degeneration LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) SK (Completed) CZ (Completed) LV (Completed) PL (Completed) BG (Completed) ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2014-003229-17 Sponsor Protocol Number: Protocol1 Start Date*: 2014-10-06
    Sponsor Name:Inst of OPhthalmology, Lund University
    Full Title: To compare the effect of Eylea given every other month after three injections to treatment with a gradual extension intervals. and examine retinal function with electroretinography (ERG) in patient...
    Medical condition: To evaluate if Aflibercept given every eighth week from start after an initial loading dose in age-related macular degeneration (AMD), is as effective as dosing as "Treat and extend" where treati...
    Disease:
    Population Age: Elderly Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2009-016158-42 Sponsor Protocol Number: IT-04-1-8-09 Start Date*: 2009-12-23
    Sponsor Name:U.L.S.S. 16
    Full Title: Efficacy of intravitreal bevacizumab for exudative age-related macular degeneration.
    Medical condition: Exudative age-related macular degeneration
    Disease: Version SOC Term Classification Code Term Level
    12.1 10015902 Exudative senile macular degeneration of retina LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2013-005393-22 Sponsor Protocol Number: RETIRD04 Start Date*: 2016-11-03
    Sponsor Name:QLT Inc.
    Full Title: A Study of the Efficacy and Safety of QLT091001 in Subjects with Inherited Retinal Disease (IRD) Caused by Mutation in Retinal Pigment Epithelium Protein 65 (RPE65) or Lecithin:Retinol Acyltransfer...
    Medical condition: Inherited retinal disease (IRD) phenotypically diagnosed as Leber congenital amaurosis (LCA) or retinitis pigmentosa (RP) caused by mutations in the retinal pigment epithelium protein 65 (RPE65) or...
    Disease: Version SOC Term Classification Code Term Level
    19.0 10010331 - Congenital, familial and genetic disorders 10038914 Retinitis pigmentosa PT
    19.0 10010331 - Congenital, familial and genetic disorders 10070667 Leber's congenital amaurosis PT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: DK (Prematurely Ended) NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2006-001200-36 Sponsor Protocol Number: AVA001 Start Date*: 2006-09-18
    Sponsor Name:St. Eriks Eye Hospital [...]
    1. St. Eriks Eye Hospital
    2.
    3. St. Eriks Eye Hospital
    4.
    Full Title: A prospective, randomized, masked and controlled trial of intravitreal bevacizumab (Avastin) versus verteporfin photodynamic therapy (PDT) in patients with neovascular age-related macular degenera...
    Medical condition: Age-related macular degeneration (AMD) is the leading cause of visual impairment and social blindness in people 60 years or older. Approximately 75% of patients with severe visual loss exhibit ne...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2014-001640-38 Sponsor Protocol Number: ATTRACT Start Date*: 2014-08-08
    Sponsor Name:CHU DE POITIERS
    Full Title: Efficacy of Aflibercept (Eylea®) on Type 3 choroidal neovascularization.
    Medical condition: Retinal diseases (type 3 choroidal neovascularization)
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004853 10060837 Choroidal neovascularization LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2019-000716-28 Sponsor Protocol Number: CRTH258A2303 Start Date*: 2019-09-02
    Sponsor Name:Novartis Pharma AG
    Full Title: A 64-week, two-arm, randomized, double-masked, multi-center, phase IIIb study assessing the efficacy and safety of brolucizumab 6 mg compared to aflibercept 2 mg in a treat-to-control regimen in pa...
    Medical condition: neovascular age-related macular degeneration
    Disease: Version SOC Term Classification Code Term Level
    20.0 10015919 - Eye disorders 10071129 Neovascular age-related macular degeneration PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PT (Completed) IT (Ongoing) CZ (Completed) SE (Completed) GB (GB - no longer in EU/EEA) ES (Completed) BE (Completed) DE (Completed) NL (Completed)
    Trial results: View results
    EudraCT Number: 2020-002452-20 Sponsor Protocol Number: CRTH258AIT04 Start Date*: 2021-01-13
    Sponsor Name:NOVARTIS FARMA S.P.A.
    Full Title: One year, single arm, open label, multicenter, phase IV study using multimodal imaging to guide disease activity assessment through innovative early predictive anatomical biomarkers of fluid resolu...
    Medical condition: Age-related neovascular macular degeneration
    Disease: Version SOC Term Classification Code Term Level
    20.0 10015919 - Eye disorders 10071129 Neovascular age-related macular degeneration PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2015-002302-36 Sponsor Protocol Number: MATE2015 Start Date*: 2018-02-06
    Sponsor Name:York Teaching Hospital
    Full Title: Treating neovascular age-related Macular Degeneration with Aflibercept:A multi-centre randomized controlled trial comparing Standard Care with an individualised Treat and Extend regimen.
    Medical condition: Neovascular Age-related macular degeneration
    Disease: Version SOC Term Classification Code Term Level
    20.1 10015919 - Eye disorders 10064930 Age-related macular degeneration PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: View results
    EudraCT Number: 2019-004145-33 Sponsor Protocol Number: CRTH258AFR03 Start Date*: 2020-04-07
    Sponsor Name:Novartis Pharma S.A.S
    Full Title: A one-year, single-arm, open-label, multicenter study assessing the effect of brolucizumab on disease control in adult patients with suboptimal anatomically controlled neovascular age-related macul...
    Medical condition: neovascular age-related macular degeneration
    Disease: Version SOC Term Classification Code Term Level
    20.0 10015919 - Eye disorders 10071129 Neovascular age-related macular degeneration PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2009-014612-34 Sponsor Protocol Number: CRFB002APT02T Start Date*: 2011-09-12
    Sponsor Name:AIBILI - Association for Innovation and Biomedical Research on Light and Image
    Full Title: Prospective, multicenter, open-label study to evaluate the safety and efficacy of intravitreal ranibizumab in patients with subfoveal or juxtafoveal choroidal neovascularization (CNV) secondary to ...
    Medical condition: Patients with subfoveal or juxtafoveal choroidal neovascularization secondary to other causes than Age-related Macular Degeneration and Pathological Myopia (angioid streaks, pseudohistoplasmosis, i...
    Disease: Version SOC Term Classification Code Term Level
    13.1 10015919 - Eye disorders 10060837 Choroidal neovascularization LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PT (Ongoing)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Mon May 20 01:03:57 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA